ライフサイエンスコーパス: transforming growth factor beta

1 an CFC tissue, but surprisingly, more active transforming growth factor beta.

2 e activity of nuclear factor-kappaB, but not transforming growth factor beta.

3 tase expression was significantly induced by transforming growth factor-beta.

4 ancer, mitogen-activated protein kinase, and transforming growth factor-beta.

5 ed expression of CTLA-4, interleukin-10, and transforming growth factor-beta.

6 secreted proreparative cytokines, including transforming growth factor-beta.

7 of profibrotic gene markers, fibronectin and transforming-growth-factor-beta.

8 -1beta; 2) IL-6; 3) IL-17A; 4) IL-23; and 5) transforming growth factor- beta.

9 hat significantly increased with exposure to transforming growth factor beta 1 (TGF-beta1), a potent

10 SMAD family member 2 (SMAD2), SMAD3, SMAD4, transforming growth factor beta 1 (TGFB1), TGFB2, TGFB3,

11 We show that transforming growth factor beta 1 (TGFbeta1)-induced epi

12 evels of the negative hair growth regulators transforming growth factor beta 1 and 2 in response to H

13 death-ligand 1, programmed cell death 1, or transforming growth factor beta 1 inhibitors.

14 e subclass expressed many genes regulated by transforming growth factor beta 1 that mediate immunosup

15 Hepatic stellate cell (HSC) activation and transforming growth factor-beta 1 (TGF-beta1) expression

16 asuring fibrosis markers, proliferation, and transforming growth factor-beta 1 secretion.

17 le actin, fibronectin, collagen type 1a, and transforming growth factor-beta 1.

18 regulatory molecules revealed an increase in transforming growth factor beta-1 (p = 0.04), matrix met

19 Transforming growth factor beta-1 (TGF-beta1) induces FA

20 Transforming growth factor beta-1 (TGFbeta-1)-induced ph

21 V independently induce profibrogenic markers transforming growth factor beta-1 (TGFbeta1) (mediated b

22 nks are increased in fibrotic pathologies by transforming growth factor beta-1 (TGFbeta1).

23 Plasmid transfection was used to modulate transforming growth factor beta 2 (TGF-beta2) gene expre

24 Connective tissue growth factor (CTGF) and transforming growth factor beta 3 (TGFbeta3) were then d

25 d more collagen I (42%), collagen III (24%), transforming growth factor beta (47%) and angiotensin II

26 previously uncharacterized mechanism through transforming growth factor-beta activated kinase 1 (TAK1

27 lation of IL-1 receptor-associated kinase 1, transforming growth factor-beta activated kinase-1, Ikap

28 Transforming growth factor beta-activated kinase 1 (TAK1

29 V-A6, and EV-D68 3C(pro) proteins all cleave transforming growth factor beta-activated kinase 1 (TAK1

30 Transforming growth factor beta-activated kinase 1 (TAK1

31 zation and IL-6 expression, IkappaBalpha and transforming growth factor beta-activated kinase 1 (TAK1

32 th death domain as an upstream regulator and transforming growth factor beta-activated kinase 1 as a

33 LZTFL1 inhibits transforming growth factor beta-activated mitogen-activa

34 Here we demonstrate that transforming growth factor-beta-activated kinase 1 (TAK1

35 a/b and thereby modulating the expression of transforming growth factor-beta-activated kinase 1 (TAK1

36 tion; and CMS4 (mesenchymal, 23%), prominent transforming growth factor-beta activation, stromal inva

37 gnature characteristic of transglutaminase 2/transforming growth factor-beta activation.

38 yte-macrophage colony-stimulating factor and transforming growth factor beta alone, whereas CD14(+) c

39 ticularly robust when cells are treated with transforming growth factor-beta, an enhancer of EMT.

40 However, transforming growth factor beta and bone morphogenetic p

41 To investigate the role of transforming growth factor beta and bone morphogenetic p

42 D206 and arginase-1) and secretory products (transforming growth factor beta and interleukin-6) and d

43 gulatory cells in vivo, M2 macrophages drive transforming growth factor-beta and IL-10 conversion of

44 expression, and profibrogenic cytokines (eg, transforming growth factor-beta and IL-13) and alteratio

45 derived CD4(+) regulatory T cells expressing transforming growth factor-beta and in increased effecto

46 vs E12.5, while abundance of elements of the transforming growth factor-beta and insulin-like growth

47 RDEB mice express high levels of transforming growth factor-beta and significantly lower

48 We also discuss how mechanisms involving transforming growth factor-beta and transcriptional cofa

49 Transforming growth factor-beta and transglutaminase 2 s

50 diac reprogramming was similarly enhanced on transforming growth factor-beta and WNT inhibition and w

51 Transforming growth factor-beta and WNT inhibitors joint

52 pilla inductive signaling pathways including transforming growth factor-beta and Wnt/beta-catenin.

53 molecular markers of fibrosis (collagen and transforming growth factor-beta) and immunostaining for

54 local fibroblast activation by secretion of transforming growth factor beta, and a preneoplastic or

55 hogenetic protein, fibroblast growth factor, transforming growth factor beta, and Wnt signaling, and

56 h as proliferation-progenitor, proliferation-transforming growth factor beta, and Wnt-catenin beta1.

57 review, we summarize how the wingless (Wnt), transforming growth factor-beta, and bone morphogenetic

58 owed tumor necrosis factor-alpha, IFN-gamma, transforming growth factor-beta, and IL-13 as potential

59 tory cytokines interleukin (IL)-1beta, IL-6, transforming growth factor-beta, and tumor necrosis fact

60 macrophage inflammatory protein (MIP)-1beta, transforming growth factor-beta, and tumor necrosis fact

61 in-1, p21-activated kinase, microRNA 21, and transforming growth factor beta are also being explored

62 lecules including FOXP3, interleukin (IL)10, transforming growth factor-beta, arginase type II, chemo

63 mannose receptor-1 (CD206), interleukin-10, transforming growth factor-beta, arginase-1, matrix meta

64 gh-density hESCs localize their receptors to transforming growth factor beta at their lateral side in

65 that it involves collagen production through transforming growth factor-beta, at least in the case of

66 Mutations in the gene for the latent transforming growth factor beta binding protein 4 (LTBP4

67 rences cannot be explained by a differential transforming growth factor beta, bone morphogenetic prot

68 endothelial cells is caused by dysregulated transforming growth factor beta/bone morphogenetic prote

69 as attenuated by thrombin-induced release of transforming growth factor beta by platelets.

70 Endoglin, a transforming growth factor-beta co-receptor, is highly e

71 tifibrotic strategies include antagonists of transforming growth factor-beta, connective tissue growt

72 duction of interleukin-2, interleukin-6, and transforming growth factor-beta, cytokines known to indu

73 Transforming growth factor-beta decreased RXFP1 in both

74 beta was significantly up-regulated, whereas transforming growth factor beta down-regulated with this

75 nvolve a complex signaling network involving transforming growth factor-beta, endothelin-1, angiotens

76 nished lung injury, collagen production, and transforming growth factor-beta expression and signaling

77 ial cell expansion, and collagen type IV and transforming growth factor-beta expression were signific

78 gamma expression, rather than with FOXP3 or transforming growth factor beta expressions.

79 tensin-aldosterone system and members of the transforming growth factor-beta family play an important

80 the mature growth factor domains across the transforming growth factor-beta family.

81 CSF-1)-dependent donor macrophages, induce a transforming growth factor beta-high environment locally

82 hat further induction of Mmp-2 expression by transforming growth factor-beta I was blocked by Meg3 si

83 y both in the absence and in the presence of transforming growth factor-beta I.

84 sition on CTCs through platelet secretion of transforming growth factor beta in response to CTC activ

85 ted immune-stimulatory cytokines and reduced transforming growth factor beta in the serum.

86 Treatment with transforming growth factor beta induced some cells to ad

87 e show that loss of BRMS1 promotes basal and transforming growth factor beta-induced EMT in NSCLC cel

88 during glucose starvation of HeLa cells and transforming growth factor beta-induced epithelial-to-me

89 GCD is caused by a point mutation in the transforming growth factor-beta-induced (TGFBI) gene, lo

90 to mediate replicative senescence as well as transforming growth factor-beta-induced cellular senesce

91 Mechanistically, sphingosine ameliorates transforming growth factor-beta-induced collagen accumul

92 rmore, mimics of miR-185 and miR-186 blocked transforming growth factor-beta-induced collagen V overe

93 based selective miRNA analysis revealed that transforming growth factor-beta-induced enhanced express

94 ced collagen V overexpression and alleviated transforming growth factor-beta-induced epithelial-mesen

95 control fibroblasts and attenuated basal and transforming growth factor-beta-induced expression of CC

96 RNA-21 levels suppressed the IL10 effects on transforming growth factor-beta-induced fibrotic signali

97 Transforming growth factor-beta-induced protein (TGFBIp)

98 evel, IL10 treatment significantly inhibited transforming growth factor-beta-induced transdifferentia

99 l-like factor 11 (KLF11 , also recognized as transforming growth factor-beta-inducible early gene 2)

100 rupt TEAD factor binding and TEAD3-dependent transforming growth factor beta induction of p16 in HAoS

101 We found that a combination of the transforming growth factor-beta inhibitor SB431542 and t

102 munosuppressive cytokines interleukin 10 and transforming growth factor beta is still ongoing.

103 The transforming growth factor beta isoforms, TGF-beta1, -be

104 s IL-1beta, tumor necrosis factor alpha, and transforming growth factor beta led to actin cytoskeleto

105 Transforming growth factor-beta, matrix metalloproteinas

106 tor in both regulating COL7A1 and inhibiting transforming growth factor-beta-mediated fibrosis.

107 Subsequent analysis suggested that anti-transforming growth factor beta neutralizing antibody, w

108 alling using small molecules that target the transforming growth factor-beta or Rho-associated kinase

109 -2 complex had no effect on profibrotic (eg, transforming growth factor-beta) or type 17 immune respo

110 pulmonary disease, and mice with bleomycin-, transforming growth factor beta-, or passive cigarette s

111 tion of cytotoxic T-lymphocyte antigen 4 and transforming growth factor-beta partially abrogated the

112 capacity to suppress multiple genes from the transforming growth factor-beta pathway and the producti

113 which correlated with overactivation of the transforming growth factor-beta pathway.

114 scle (Asm) area with decreased periostin and transforming growth factor beta-positive cells within As

115 tracellular space, such as modulation of pro-transforming growth factor-beta processing, activation o

116 art by defective desmosomes and dysregulated transforming growth factor beta production and signaling

117 ted with reduced macrophage infiltration and transforming growth factor-beta production.

118 ed hepatic stellate cell activation markers (transforming growth factor-beta protein and alpha-smooth

119 growth factor beta 1 (TGFB1), TGFB2, TGFB3, transforming growth factor beta receptor 1 (TGFBR1), and

120 le cell lineage tracing following stochastic transforming growth factor beta receptor 2 (TgfbetaR2) m

121 bsence of CLCa was attributable to increased transforming growth factor beta receptor 2 (TGFbetaR2) s

122 Here, we identify this receptor as transforming growth factor beta receptor I (TGF-betaRI)

123 Transforming growth factor beta receptor II interacting

124 structures of five fragments in complex with transforming growth factor beta receptor type 1 kinase d

125 scued the lethal autoimmunity resulting from transforming growth factor-beta receptor (TGF-betaR) del

126 eceptor type 1C (ACVR1C), a component of the transforming growth factor-beta receptor superfamily.

127 own-regulation of thrombospondin 1, a latent transforming growth factor-beta receptor, and transcript

128 Transforming growth factor-betas regulate a wide range o

129 cytokines (interleukin 6, 1beta, and 23 and transforming growth factor beta) restored CD4+ Th17 cell

130 DD4L plays an important role in constraining transforming growth factor beta signaling by targeting a

131 Our results suggest that Shh and transforming growth factor beta signaling cooperate to p

132 lished a mechanism of negative regulation of transforming growth factor beta signaling mediated by th

133 iptional regulator SMAD6, which inhibits the transforming growth factor beta signaling pathway, is re

134 iptional regulator SMAD6, which inhibits the transforming growth factor beta signaling pathway, is re

135 miR-337-3p requires Notch and transforming growth factor-beta signaling and exerts a b

136 We demonstrate that transforming growth factor-beta signaling confers this p

137 which was partly attributable to blockade of transforming growth factor-beta signaling in dermal fibr

138 ncreased expression of profibrotic genes and transforming growth factor-beta signaling in SFBLs.

139 was determined on mitochondrial function and transforming growth factor-beta signaling in vitro and i

140 ed genes were significantly enriched in the "transforming growth factor-beta signaling pathway".

141 agonists, likely through suppression of the transforming growth factor-beta signaling pathway.

142 lation, suggesting that miR-542-5p increased transforming growth factor-beta signaling.

143 R-29 itself is regulated by SP1 activity and transforming growth factor-beta signaling.

144 n knockdown or supplementation did not alter transforming growth factor-beta signaling.

145 nt role in kidney fibrogenesis by modulating transforming growth factor-beta signaling.

146 mitochondrial ribosomal stress and increased transforming growth factor-beta signaling.

147 e because of myeloid deficiency of TGF-beta (transforming growth factor-beta) signaling.

148 Smad7 is an intracellular antagonist of transforming growth factor-beta signalling pathways and

149 phosphatidylinositol 3-kinase (PI3K) and the transforming growth factor-beta signalling pathways play

150 anonical Hh pathway, involving TGFbeta/SMAD (transforming growth factor-beta/Sma- and Mad-related fam

151 Activation of transforming growth factor-beta/Smad3 signaling in the d

152 eceptor, liver X factor/retinoic X receptor, transforming growth factor-beta (Smads), and hypoxia (hy

153 Furthermore, we demonstrated that transforming growth factor beta stimulation resulted in

154 ced by a combination of ErbB2 activation and transforming growth factor beta stimulation, which is kn

155 tiation factor 11 (GDF11) is a member of the transforming growth factor-beta super family of secreted

156 (or GDF8) are closely related members of the transforming growth factor beta superfamily and are ofte

157 epiregulin (EREG), and other members of the transforming growth factor beta superfamily.

158 The expression and function of transforming growth factor-beta superfamily receptors ar

159 actor 11 (GDF11) and GDF8 are members of the transforming growth factor-beta superfamily sharing 89%

160 Endoglin (CD105), a receptor of the transforming growth factor-beta superfamily, has been re

161 eased when Cav-1(-/-)T cells were exposed to transforming growth factor-beta/T-cell receptor (TCR)/CD

162 E-536) is a novel fusion protein that blocks transforming growth factor beta (TGF beta) superfamily i

163 induction of SP-A expression is repressed by transforming growth factor beta (TGF-beta) and by hypoxi

164 reatment there was a significant increase in transforming growth factor beta (TGF-beta) and concomita

165 with traction generation and is mediated by transforming growth factor beta (TGF-beta) and the migra

166 Tumor-derived transforming growth factor beta (Tgf-beta) decreased Sat

167 Transforming growth factor beta (TGF-beta) differentiall

168 EMT is induced by soluble transforming growth factor beta (TGF-beta) family member

169 Transforming growth factor beta (TGF-beta) functions as

170 To understand the cell-specific role of transforming growth factor beta (TGF-beta) in the myeloi

171 Transforming growth factor beta (TGF-beta) is a potent a

172 Transforming growth factor beta (TGF-beta) is a potent i

173 Transforming growth factor beta (TGF-beta) is an establi

174 Transforming growth factor beta (TGF-beta) is well known

175 Transforming growth factor beta (TGF-beta) isoforms are

176 The transforming growth factor beta (TGF-beta) pathway plays

177 Transforming growth factor beta (TGF-beta) pathways are

178 ng pathways, including the PI3K/PTEN/AKT and transforming growth factor beta (TGF-beta) pathways have

179 l as thymic stromal lymphopoietin (TSLP) and transforming growth factor beta (TGF-beta) plasma levels

180 We show that the type III transforming growth factor beta (TGF-beta) receptor (Tbe

181 ave previously determined that type I and II transforming growth factor beta (TGF-beta) receptors (Tb

182 o signaling have also been reported to block transforming growth factor beta (TGF-beta) responses, ba

183 near-infrared light-triggered activation of transforming growth factor beta (TGF-beta) signal transd

184 in genes encoding various components of the transforming growth factor beta (TGF-beta) signaling cas

185 , which in turn activates the STAT3-mediated transforming growth factor beta (TGF-beta) signaling pat

186 t role in bone morphogenic protein (BMP) and transforming growth factor beta (TGF-beta) signaling pat

187 transition (EMT) by regulating the canonical transforming growth factor beta (TGF-beta) signaling pat

188 plays a central role in the amplification of transforming growth factor beta (TGF-beta) signaling res

189 d pathways: NF-kappaB (p65) transactivation, transforming growth factor beta (TGF-beta) signaling, an

190 xpression, a microRNA cluster that regulates transforming growth factor beta (TGF-beta) signaling.

191 been linked to NR4A1-dependent regulation of transforming growth factor beta (TGF-beta) signaling.

192 extracellular matrix, or decrease canonical transforming growth factor beta (TGF-beta) signaling.

193 Inhbb), an activin subunit and member of the transforming growth factor beta (TGF-beta) superfamily,

194 Kruppel-like factor 15 (Klf15), by both the transforming growth factor beta (TGF-beta) transcription

195 the prototypical prosclerotic growth factor, transforming growth factor beta (TGF-beta), is thought t

196 cules include collagen types I, III, and IV, transforming growth factor beta (TGF-beta), TGF-beta rec

197 fied mutations in two genes-MAP3K7, encoding transforming growth factor beta (TGF-beta)-activated kin

198 MAP3K7 encodes transforming growth factor beta (TGF-beta)-activated kin

199 Notably, expansion was mediated by transforming growth factor beta (TGF-beta)-containing ex

200 ShcA is an important mediator of ErbB2- and transforming growth factor beta (TGF-beta)-induced breas

201 screened for chemical compounds that reverse transforming growth factor beta (TGF-beta)-induced epith

202 Transforming growth factor beta (TGF-beta)-induced migra

203 e found to be an important source of cardiac transforming growth factor-beta (TGF-beta) and PAI-1 reg

204 ibition of bone morphogenetic protein (BMP), transforming growth factor-beta (TGF-beta) and Wnt signa

205 the various regulatory factors tested, only transforming growth factor-beta (TGF-beta) demonstrated

206 Its ability to bind and antagonize the transforming growth factor-beta (TGF-beta) family ligand

207 Transforming growth factor-beta (TGF-beta) family ligand

208 The transforming growth factor-beta (TGF-beta) family of cyt

209 The transforming growth factor-beta (TGF-beta) family of gro

210 ave markers that denote tissue residency and transforming growth factor-beta (TGF-beta) imprinting.

211 Furthermore, reduction of nephrin by transforming growth factor-beta (TGF-beta) in podocytes

212 Transforming growth factor-beta (TGF-beta) is known to b

213 proliferation and differentiation actions of transforming growth factor-beta (TGF-beta) ligand family

214 The transforming growth factor-beta (TGF-beta) network of li

215 In the transforming growth factor-beta (Tgf-beta) pathway, expo

216 screen in human FA fibroblasts, we identify transforming growth factor-beta (TGF-beta) pathway-media

217 of both XPC and DDB1 through activating the transforming growth factor-beta (TGF-beta) pathway.

218 Transforming growth factor-beta (TGF-beta) plays an impo

219 acting through Toll-like receptors, induced transforming growth factor-beta (TGF-beta) production by

220 signature converging on key pathways such as transforming growth factor-beta (TGF-beta) receptor acti

221 Transforming growth factor-beta (TGF-beta) receptor olig

222 CD103(-) T cells did not require transforming growth factor-beta (TGF-beta) signaling but

223 nd that human PDACs with impaired epithelial transforming growth factor-beta (TGF-beta) signaling hav

224 The role of transforming growth factor-beta (TGF-beta) signaling in

225 Transforming growth factor-beta (TGF-beta) signaling is

226 The transforming growth factor-beta (TGF-beta) signaling pat

227 Hyperactivation of transforming growth factor-beta (TGF-beta) signaling pat

228 teins are central mediators in the canonical transforming growth factor-beta (TGF-beta) signaling pat

229 The transforming growth factor-beta (TGF-beta) signaling pat

230 SIGNIFICANCE STATEMENT We show that reducing Transforming growth factor-beta (TGF-beta) signaling pro

231 Here, we show that transforming growth factor-beta (TGF-beta) signaling via

232 umulation, extracellular matrix degradation, transforming growth factor-beta (TGF-beta) signaling, co

233 clear-shuttling transcriptional mediators of transforming growth factor-beta (TGF-beta) signaling.

234 We have previously demonstrated that transforming growth factor-beta (TGF-beta) signalling co

235 ere we show that epidermal Hedgehog (Hh) and Transforming growth factor-beta (TGF-beta) signalling me

236 eover, RNA-sequencing analysis shows altered transforming growth factor-beta (TGF-beta) signalling.

237 We have shown a vital role for transforming growth factor-beta (TGF-beta) signals in sa

238 Transforming growth factor-beta (TGF-beta) signals throu

239 o known as MIC-1, is a distant member of the transforming growth factor-beta (TGF-beta) superfamily a

240 lammatory drug-activated gene-1 (NAG-1) is a transforming growth factor-beta (TGF-beta) superfamily p

241 also observed altered regulation of multiple transforming growth factor-beta (TGF-beta) target genes.

242 ABSTRACT: Transforming growth factor-beta (TGF-beta), RhoA/Rho-kin

243 Transforming growth factor-beta (TGF-beta), serine prote

244 f regulatory T cells (Treg cells) induced by transforming growth factor-beta (TGF-beta), we identifie

245 Transforming growth factor-beta (TGF-beta)-activated Sma

246 t analysis of gene expression changes during transforming growth factor-beta (TGF-beta)-induced EMT i

247 that the STAT3 signaling pathway attenuates transforming growth factor-beta (TGF-beta)-induced respo

248 injury produced by airway disease triggers a transforming growth factor-beta (TGF-beta)-mediated epig

249 Papillary thyroid carcinoma overexpress transforming growth factor-beta (TGF-beta).

250 imarily, but not exclusively, in response to transforming growth factor-beta (TGF-beta).

251 and also required a novel intersection with transforming growth factor-beta (TGF-beta)/SMAD signalin

252 ced expression of Wnt target genes (axin-2), transforming growth factor-beta (TGF-beta1) and collagen

253 -mesenchymal transition (EMT) in response to transforming growth factor-beta (TGF-beta1) become activ

254 KEY POINTS: Transforming growth-factor-beta (TGF-beta) and RhoA/Rho-

255 lated type 2 (IL-4 and IL-5) and regulatory (transforming growth factor beta [TGF-beta]) cytokines.

256 IL-5, IL-9, IL-10, IL-13, IL-27, IL-37, and transforming growth factor beta [TGF-beta]).

257 tine leads to release of fossilized factors (transforming growth factor-beta [TGF-beta] and bone morp

258 ctor a [VEGFa], angiopoietin 1 (Ang1), Ang2, transforming growth factor-beta [TGF-beta], and platelet

259 Activin, a member of the transforming growth factor-beta (TGFB) family, might be

260 er and serves as a common downstream node of transforming growth factor beta (TGFbeta) and bone morph

261 ber of key signaling pathways, including the transforming growth factor beta (TGFbeta) and epithelial

262 Transforming growth factor beta (TGFbeta) and fibroblast

263 Members of the transforming growth factor beta (TGFbeta) cytokine famil

264 e that low-dosage/short-duration exposure to transforming growth factor beta (TGFbeta) induces partia

265 ent phenotypic differences, dysregulation of transforming growth factor beta (TGFbeta) is a common fa

266 Transforming growth factor beta (TGFbeta) is a pleiotrop

267 Transforming growth factor beta (TGFbeta) is important i

268 Transforming growth factor beta (TGFbeta) is instrumenta

269 mong tumour-associated inflammatory factors, transforming growth factor beta (TGFbeta) is regarded as

270 Here we demonstrate that transforming growth factor beta (TGFbeta) is required fo

271 a family of signal transduction molecules in transforming growth factor beta (TGFbeta) ligand pathway

272 n of extracellular matrix (ECM)-bound latent transforming growth factor beta (TGFbeta) ligands and st

273 The transforming growth factor beta (TGFbeta) pathway plays

274 as TIEG1, plays essential roles in mediating transforming growth factor beta (TGFbeta) signaling and

275 Microarray studies identified impaired transforming growth factor beta (TGFbeta) signaling in c

276 In pausing-deficient embryos, the transforming growth factor beta (TGFbeta) signaling is e

277 dependent protein kinase (PDK1) and enhanced transforming growth factor beta (TGFbeta) signaling rath

278 Non-canonical transforming growth factor beta (TGFbeta) signaling thro

279 2-HER3 signaling, or A83-01, an inhibitor of transforming growth factor beta (TGFbeta) signaling.

280 d that these proteoglycans were dependent on transforming growth factor beta (TGFbeta) signaling.

281 we investigated the impact of LTBP4 loss on transforming growth factor beta (TGFbeta) signaling.

282 Transforming growth factor beta (TGFbeta) signalling is

283 Transforming growth factor beta (TGFbeta) signalling is

284 crophage colony-stimulating factor (GM-CSF), transforming growth factor beta (TGFbeta), and bone morp

285 nse to anti-proliferative cytokines, such as transforming growth factor beta (TGFbeta), and directly

286 in (IL6) beta2SP(+/-) LSCs was activated by transforming growth factor beta (TGFbeta)-activated kina

287 SCs, both TANGO1 and the UPR were induced by transforming growth factor beta (TGFbeta).

288 d that DMF blocks the profibrotic effects of transforming growth factor-beta (TGFbeta) in SSc skin fi

289 r (TGF) beta pathway because both a specific transforming growth factor-beta (TGFbeta) inhibitor (SB4

290 integrin alphavbeta8-mediated activation of transforming growth factor-beta (TGFbeta).

291 ding osteopontin, and LTBP4, encoding latent transforming growth factor beta [TGFbeta]-binding protei

292 nsists of platelet-derived growth factor and transforming growth factor-beta that increase proliferat

293 with amplification of cytostatic effects of transforming growth factor-beta through induction of cel

294 lowing isotropic chondrogenic induction with transforming growth factor beta to set up a dual-compart

295 Transforming growth factor beta treatment induced gene-b

296 Transforming growth factor beta type III receptor (Tbeta

297 Conditional deletion of transforming growth factor-beta type II receptor in Wt1(

298 in kinases, tight junctions, focal adhesion, transforming growth factor-beta, vascular smooth muscle

299 that these HCV-infected hepatocytes express transforming growth factor beta, which activates stromal

300 Smad7 is a negative regulator of transforming growth factor-beta, which is increased in t